N-(4-chlorophenyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-chlorophenyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine
• 英文别名: US9840501, Example 18
• 化学式: C₁₅H₁₆ClN₃O
• 分子量: 289.765
• InChiKey: UBOVDXSEPYEZIZ-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] MORPHOLIN-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS MORPHOLINE-PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015165835A1

  公开（公告）日：2015-11-05

  The present invention relates to compounds of formula (I) wherein X is CR or N; R is hydrogen, halogen or lower alkyl; L is a bond, -C(O)- or -C(O)NH-; Ar is phenyl or a five or six membered heteroaryl group, containing one or two N atoms; R1 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or cycloalkyl; n is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下式（I）的化合物，其中X为CR或N；R为氢、卤素或较低的烷基；L为键，-C（O）-或-C（O）NH-；Ar为苯基或含有一个或两个N原子的五元或六元杂环芳基；R1为卤素、较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基或环烷基；n为0、1、2或3；或其药学适宜的酸加合物，所有外消旋混合物，所有对应的对映体和/或光学异构体，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍（ADHD）、与压力有关的障碍、精神障碍、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢障碍、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• MORPHOLIN-PYRIDINE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3137459A1

  公开（公告）日：2017-03-08
• MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3137459B1

  公开（公告）日：2018-05-23
• US9840501B2
  申请人：——

  公开号：US9840501B2

  公开（公告）日：2017-12-12
• [EN] MORPHOLIN-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE MORPHOLINE-PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015165085A1

  公开（公告）日：2015-11-05

  The present invention relates to compounds of formula (I), wherein X is CH or N; L is a bond, -C(O)- or -C(O)NH-; Ar is phenyl or a five or six membered heteroaryl group, containing one or two N atoms; R1is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or cycloalkyl; n is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures,all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder,attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.